Nava Therapeutics raises $89 million to advance lipid nanoparticle platform targeting bone marrow, immune cells and kidney
read at Endpoints ↗DealPositive
Nava Therapeutics, a stealth-mode biotech, announced it has secured $89 million in financing, according to a statement to Endpoints News.
The capital will support development of a next generation lipid nanoparticle platform designed to deliver therapeutic payloads to the bone marrow, immune cells and the kidney.
The funding round underscores investor interest in novel delivery technologies that could broaden the reach of cell and gene therapies.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Nava Therapeutics emerges with $89M for lipid nanoparticles”
read at Endpoints ↗92 words · retrieved Jul 15
comments(0)
5-min edit window · permanent after that